Reshaping Anticoagulation: Factor XI Inhibition in Thrombosis Management

Abstract

Factor XI is almost dispensable for haemostasis, but its role in thrombosis has become increasingly clear. Targeting factor XI could potentially prevent thrombosis with little or no effect on haemostasis. This review explains the underlying mechanisms of thrombosis and haemostasis and elucidates the rationale for factor XI inhibitors based on the pathophysiology and epidemiological and pre-clinical data. It further outlines the different modes for factor XI inhibition. Finally, the article provides an overview of the current clinical evidence and the ongoing trials for factor XI inhibitors in various clinical indications.

Zusammenfassung

Faktor XI spielt eine entscheidende Rolle bei der Thrombose, ist jedoch für die Hämostase nahezu entbehrlich. Die gezielte Beeinflussung von Faktor XI könnte daher dazu beitragen, Thrombose von der Hämostase zu trennen. Diese Übersichtsarbeit erläutert die zugrunde liegenden Mechanismen von Thrombose und Hämostase und erläutert die Begründung für die Verwendung von Faktor-XI-Inhibitoren auf der Grundlage der Pathophysiologie sowie epidemiologischer und präklinischer Daten. Darüber hinaus werden die vielfältigen Ansätze zur Faktor-XI-Inhibition beschrieben. Schließlich bietet der Artikel einen umfassenden Überblick über die bestehenden klinischen Belege für Faktor-XI-Inhibitoren in verschiedenen klinischen Kontexten und stellt eine Übersicht über laufende Studien bereit.

Keywords

factor XI inhibition - factor XI inhibitors - thrombosis - bleeding - FXI

Schlüsselwörter

Faktor-XI-Inhibition - Faktor-XI-Inhibitoren - FXI - Thrombose - Blutung

• References

• 1 Lozano R, Naghavi M, Foreman K. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859) 2095-2128
• 2 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921) 955-962
• 3 Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012; 110 (03) 453-460
• 4 Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 2015; 13 (11) 2012-2020
• 5 Granger CB, Alexander JH, McMurray JJV. et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
• 6 Giugliano RP, Ruff CT, Braunwald E. et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
• 7 Patel MR, Mahaffey KW, Garg J. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
• 8 Connolly SJ, Ezekowitz MD, Yusuf S. et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
• 9 Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342 (10) 696-701
• 10 Yang DT, Flanders MM, Kim H, Rodgers GM. Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events. Am J Clin Pathol 2006; 126 (03) 411-415
• 11 Cushman M, O'Meara ES, Folsom AR, Heckbert SR. Coagulation factors IX through XIII and the risk of future venous thrombosis: the longitudinal investigation of thromboembolism etiology. Blood 2009; 114 (14) 2878-2883
• 12 Salomon O, Steinberg DM, Zucker M, Varon D, Zivelin A, Seligsohn U. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost 2011; 105 (02) 269-273
• 13 Salomon O, Steinberg DM, Dardik R. et al. Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost 2003; 1 (04) 658-661
• 14 Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111 (08) 4113-4117
• 15 Preis M, Hirsch J, Kotler A. et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood 2017; 129 (09) 1210-1215
• 16 Salomon O, Steinberg DM, Seligshon U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia 2006; 12 (05) 490-493
• 17 Wang X, Cheng Q, Xu L. et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005; 3 (04) 695-702
• 18 Tucker EI, Marzec UM, White TC. et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood 2009; 113 (04) 936-944
• 19 Crosby JR, Marzec U, Revenko AS. et al. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol 2013; 33 (07) 1670-1678
• 20 Decrem Y, Rath G, Blasioli V. et al. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med 2009; 206 (11) 2381-2395
• 21 Pireaux V, Tassignon J, Demoulin S. et al. Anticoagulation with an inhibitor of factors XIa and XIIa during cardiopulmonary bypass. J Am Coll Cardiol 2019; 74 (17) 2178-2189
• 22 Chen W, Carvalho LPD, Chan MY, Kini RM, Kang TS. Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity. J Thromb Haemost 2015; 13 (02) 248-261
• 23 Verhamme P, Tangelder M, Verhaeghe R. et al; TB-402 Study Group. Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial. J Thromb Haemost 2011; 9 (04) 664-671
• 24 Verhamme P, Gunn S, Sonesson E. et al. Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial. Thromb Haemost 2013; 109 (06) 1091-1098
• 25 Verhamme P, Yi BA, Segers A. et al; ANT-005 TKA Investigators. Abelacimab for prevention of venous thromboembolism. N Engl J Med 2021; 385 (07) 609-617
• 26 Weitz JI, Bauersachs R, Becker B. et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA 2020; 323 (02) 130-139
• 27 Lorentz CU, Tucker EI, Verbout NG. et al. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood 2021; 138 (22) 2173-2184
• 28 Walsh M, Bethune C, Smyth A. et al; CS4 Investigators. Phase 2 study of the factor XI antisense inhibitor IONIS-FXI_Rx in patients with ESRD. Kidney Int Rep 2021; 7 (02) 200-209
• 29 Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes from the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs,. Distributes and Removes the Study Drug (RE-THINc ESRD). Accessed November 30, 2023 at: https://clinicaltrials.gov/study/NCT04534114
• 30 Piccini JP, Caso V, Connolly SJ. et al; PACIFIC-AF Investigators. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 2022; 399 (10333): 1383-1390
• 31 Weitz JI, Strony J, Ageno W. et al; AXIOMATIC-TKR Investigators. Milvexian for the prevention of venous thromboembolism. N Engl J Med 2021; 385 (23) 2161-2172
• 32 Donkor DA, Bhakta V, Eltringham-Smith LJ, Stafford AR, Weitz JI, Sheffield WP. Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa. Sci Rep 2017; 7 (01) 2102
• 33 Woodruff RS, Ivanov I, Verhamme IM, Sun MF, Gailani D, Sullenger BA. Generation and characterization of aptamers targeting factor XIa. Thromb Res 2017; 156: 134-141
• 34 Büller HR, Bethune C, Bhanot S. et al; FXI-ASO TKA Investigators. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015; 372 (03) 232-240
• 35 Nopp S, Kraemmer D, Ay C. Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence. Front Cardiovasc Med 2022; 9: 903029
• 36 Presume J, Ferreira J, Ribeiras R, Mendes M. Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery - systematic review and meta-analysis. J Thromb Haemost 2022; 20 (12) 2930-2938
• 37 Lloyd-Jones DM, Wang TJ, Leip EP. et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110 (09) 1042-1046
• 38 Staerk L, Gerds TA, Lip GYH. et al. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. J Intern Med 2018; 283 (01) 45-55
• 39 Ruff CA. Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared With Open-Label Rivaroxaban in Patients with Atrial Fibrillation (AZALEA-TIMI 71). Paper presented at the American Heart Association Scientific Sessions, Philadelphia, PA, November 12, 2023 . Accessed November 30, 2023 at: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/11/10/22/46/azalea-timi-71#references-for-article
• 40 Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76). Accessed November 30, 2023 at: https://clinicaltrials.gov/study/NCT05712200
• 41 A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People with Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke (OCEANIC-AF). Accessed November 30, 2023 at: https://clinicaltrials.gov/study/NCT05643573
• 42 A Study of Milvexian versus Apixaban in Participants with Atrial Fibrillation (LIBREXIA-AF). Accessed November 30, 2023 at: https://clinicaltrials.gov/study/NCT05757869
• 43 Kumar S, Lim E, Covic A. et al. Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol 2019; 74 (17) 2204-2215
• 44 Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc 2020; 9 (13) e017559
• 45 A Study of ISIS 416858 Administered Subcutaneously to Participants with End-Stage Renal Disease (ESRD) on Hemodialysis (EMERALD). Accessed November 30, 2023 at: https://clinicaltrials.gov/study/NCT03358030
• 46 Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients with Kidney Failure Requiring Regular Hemodialysis (CONVERT). Accessed November 30, 2023 at: https://clinicaltrials.gov/study/NCT04523220
• 47 Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants with End Stage Renal Disease Receiving Hemodialysis. (FXI Hemodialysis Study) (MK-2060-007). Accessed November 30, 2023 at: https://clinicaltrials.gov/study/NCT05027074
• 48 Flach C, Muruet W, Wolfe CDA, Bhalla A, Douiri A. Risk and secondary prevention of stroke recurrence: a population-base cohort study. Stroke 2020; 51 (08) 2435-2444
• 49 Shoamanesh A, Mundl H, Smith EE. et al; PACIFIC-Stroke Investigators. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 2022; 400 (10357) 997-1007
• 50 Sharma M, Molina CA, Hankey GJ. Efficacy and safety of the FXIa inhibitor milvexian for secondary stroke prevention: final results of the AXIOMATIC-SSP dose-finding randomized trial. Paper presented at the European Society of Cardiology Congress, Barcelona, Spain, August 28, 2022 . Accessed November 30, 2023 at: https://www.acc.org/latest-in-cardiology/clinical-trials/2022/08/27/04/12/axiomatic-ssp
• 51 A Study of Milvexian in Participants after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack (LIBREXIA-STROKE). Accessed November 30, 2023 at: https://clinicaltrials.gov/study/NCT05702034
• 52 A Study to Test Asundexian to Prevent a Clot-Related Stroke in Participants after an Acute Ischemic Stroke or High-risk TIA/Mini-stroke (Transient Ischemic Attack) (OCEANIC-STROKE). Accessed November 30, 2023 at: https://clinicaltrials.gov/study/NCT05686070
• 53 Smolina K, Wright FL, Rayner M, Goldacre MJ. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes 2012; 5 (04) 532-540
• 54 Eikelboom JW, Connolly SJ, Bosch J. et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377 (14) 1319-1330
• 55 Mega JL, Braunwald E, Wiviott SD. et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (01) 9-19
• 56 Rao SV, Kirsch B, Bhatt DL. et al; PACIFIC AMI Investigators. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation 2022; 146 (16) 1196-1206
• 57 A Study of Milvexian in Participants after a Recent Acute Coronary Syndrome (LIBREXIA-ACS). Accessed November 30, 2023 at: https://clinicaltrials.gov/study/NCT05754957
• 58 A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-Associated VTE (ASTER). Accessed November 30, 2023 at: https://clinicaltrials.gov/study/NCT05171049
• 59 A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE (MAGNOLIA). Accessed November 30, 2023 at: https://clinicaltrials.gov/study/NCT05171075
• 60 Salomon O, Gailani D. A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors. J Thromb Haemost 2022; 20 (01) 32-38